Carrie B. Lee
About
Carrie B. Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Carrie B. Lee has authored 57 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Carrie B. Lee's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Carrie B. Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Carrie B. Lee collaborates with scholars based in United States, Canada and United Kingdom. Carrie B. Lee's co-authors include Mark A. Socinski, Thomas E. Stinchcombe, Julian Rosenman, Brian C. Jensen, Allison M. Deal, Timothy M. Zagar, Lawrence B. Marks, Panayiotis Mavroidis, Kyle Wang and Matthew B. Lipner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
Carrie B. Lee
56 papers receiving 1.6k citations
Hit Papers
Peers
Carrie B. Lee
Éric Dansin France
Nils‐Olof Bengtsson Sweden
Federica Cuppone Italy
Panos Fidias United States
Antoine Adenis France
Ingvil Mjaaland Norway
Brian F. Chapin United States
Matteo Giaj Levra France
G. Robinet France
Guy A. Van Hazel Australia
Citations per year, relative to Carrie B. Lee Carrie B. Lee (= 1×)
peers
Éric Dansin
Countries citing papers authored by Carrie B. Lee
Since
Specialization
Citations
This map shows the geographic impact of Carrie B. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carrie B. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carrie B. Lee more than expected).
Fields of papers citing papers by Carrie B. Lee
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carrie B. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carrie B. Lee. The network helps show where Carrie B. Lee may publish in the future.
Co-authorship network of co-authors of Carrie B. Lee
This figure shows the co-authorship network connecting the top 25 collaborators of Carrie B. Lee. A scholar is included among the top collaborators of Carrie B. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carrie B. Lee. Carrie B. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hirata, Hirokazu, et al.. (2025). Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report. JTO Clinical and Research Reports. 6(4). 100787–100787.
2.
Stover, Angela M., Allison M. Deal, Ashley A. Weiner, et al.. (2025). Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare© Study. Clinical Lung Cancer. 26(8). e660–e669.e1.
3.
Zhu, Haiying, et al.. (2023). Genotypic testing improves detection of antiviral resistance in human herpes simplex virus. Journal of Clinical Virology. 167. 105554–105554.
4.
Karachaliou, Georgia Sofia, Rached Alkallas, Nirali M. Patel, et al.. (2022). The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer. 22(1). 38–38.
5.
Deng, Ruixia, Bin Yan, Carrie B. Lee, et al.. (2022). Temporal Control of the WNT Signaling Pathway During Cardiac Differentiation Impacts Upon the Maturation State of Human Pluripotent Stem Cell Derived Cardiomyocytes. Frontiers in Molecular Biosciences. 9. 714008–714008.
6.
Wang, Kyle, Hayley Malkin, Kevin A. Pearlstein, et al.. (2021). Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 112(1). 188–196.
7.
Patel, Shetal, David E. Gerber, Allison M. Deal, et al.. (2021). Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 666691–666691.
8.
Lee, Carrie B., Theresa L. Werner, Allison M. Deal, et al.. (2020). Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers. JCO Oncology Practice. 17(1). e77–e93.
9.
Kaidar‐Person, Orit, Timothy M. Zagar, Allison M. Deal, et al.. (2017). The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases. Anti-Cancer Drugs. 28(6). 669–675.
10.
Wang, Kyle, Kevin A. Pearlstein, Allison M. Deal, et al.. (2017). Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiotherapy and Oncology. 125(2). 293–300.
11.
Franceschi, Ana M., Stergios J. Moschos, Carey K. Anders, et al.. (2016). Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma. Journal of Computer Assisted Tomography. 40(5). 803–805.
12.
Lee, Carrie B., et al.. (2015). MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor. Journal of Thoracic Oncology. 10(12). e113–e114.
13.
Weiss, Jared, Liza C. Villaruz, Jonathon J. O’Brien, et al.. (2015). Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer. Clinical Lung Cancer. 17(2). 128–132.
14.
Stinchcombe, Thomas E., Joanna Roder, Amy H. Peterman, et al.. (2013). A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(4). 443–451.
15.
Stinchcombe, Thomas E., Amy H. Peterman, Carrie B. Lee, et al.. (2011). A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(9). 1569–1577.
16.
Wilkerson, Matthew D., Xiaoying Yin, Katherine A. Hoadley, et al.. (2010). Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types. Clinical Cancer Research. 16(19). 4864–4875.
17.
Lee, Carrie B., Thomas E. Stinchcombe, Dominic T. Moore, et al.. (2009). Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(1). 74–79.
18.
Lee, Carrie B. & Mark A. Socinski. (2007). Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials. Reviews on Recent Clinical Trials. 2(2). 117–120.
19.
Stinchcombe, Thomas E., Carrie B. Lee, & Mark A. Socinski. (2006). Current Approaches to Advanced-Stage Non–Small-Cell Lung Cancer: First-Line Therapy in Patients with a Good Functional Status. Clinical Lung Cancer. 7. S111–S117.
20.
Lee, Carrie B., Thomas E. Stinchcombe, Julian Rosenman, & Mark A. Socinski. (2006). Therapeutic Advances in Local-Regional Therapy for Stage III Non-Small-Cell Lung Cancer: Evolving Role of Dose-Escalated Conformal (3-Dimensional) Radiation Therapy. Clinical Lung Cancer. 8(3). 195–202.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Éric Dansin Breakdown of academic impact, for papers by Nils‐Olof Bengtsson Breakdown of academic impact, for papers by Federica Cuppone Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Antoine Adenis Breakdown of academic impact, for papers by Ingvil Mjaaland Breakdown of academic impact, for papers by Brian F. Chapin Breakdown of academic impact, for papers by Matteo Giaj Levra Breakdown of academic impact, for papers by G. Robinet Breakdown of academic impact, for papers by Guy A. Van Hazel